Till Schoofs, MD

Director, Clinical Development Infectious Disease
Moderna, Inc
Cambridge, MA, United States

Disclosure(s): Moderna, Inc: Employee, Stocks/Bonds (Public Company)

Presentation(s):

• 575 - Safety and Immunogenicity of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial

  Saturday, October 19, 2024
  1:45 PM – 1:57 PM US PT